239 related articles for article (PubMed ID: 34662810)
1. Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.
Broadbent R; Wheatley R; Stajer S; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E; McNamara MG
Cancer Treat Rev; 2021 Dec; 101():102299. PubMed ID: 34662810
[TBL] [Abstract][Full Text] [Related]
2. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
[TBL] [Abstract][Full Text] [Related]
3. Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours.
Chiramel J; Almond R; Slagter A; Khan A; Wang X; Lim KHJ; Frizziero M; Chakrabarty B; Minicozzi A; Lamarca A; Mansoor W; Hubner RA; Valle JW; McNamara MG
World J Clin Oncol; 2020 Apr; 11(4):205-216. PubMed ID: 32355642
[TBL] [Abstract][Full Text] [Related]
4. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
[No Abstract] [Full Text] [Related]
5. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study.
Poleé IN; Hermans BCM; van der Zwan JM; Bouwense SAW; Dercksen MW; Eskens FALM; Havekes B; Hofland J; Kerkhofs TMA; Klümpen HJ; Latten-Jansen LM; Speel EM; Verburg FA; Walenkamp AME; Geurts SME; de Vos-Geelen J
Eur J Cancer; 2022 Sep; 172():252-263. PubMed ID: 35803176
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years.
Baptiste GG; Postlewait LM; Ethun CG; Le N; McInnis MR; Russell MC; Winer JH; Kooby DA; Staley CA; Maithel SK; Cardona K
J Surg Oncol; 2016 Aug; 114(2):163-9. PubMed ID: 27157897
[TBL] [Abstract][Full Text] [Related]
8. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.
Pommergaard HC; Nielsen K; Sorbye H; Federspiel B; Tabaksblat EM; Vestermark LW; Janson ET; Hansen CP; Ladekarl M; Garresori H; Hjortland GO; Sundlöv A; Galleberg R; Knigge P; Kjaer A; Langer SW; Knigge U
J Neuroendocrinol; 2021 May; 33(5):e12967. PubMed ID: 33769624
[TBL] [Abstract][Full Text] [Related]
9. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.
Li MX; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Zhang XF; Pawlik TM
J Surg Oncol; 2022 Sep; 126(4):689-697. PubMed ID: 35616186
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal Surgery of Neuroendocrine Neoplasms.
Hansen CP; Olsen IH; Knigge U
Front Horm Res; 2015; 44():149-63. PubMed ID: 26303710
[TBL] [Abstract][Full Text] [Related]
11. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
13. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
14. Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria.
Martin JA; Warner RR; Wisnivesky JP; Kim MK
Eur J Cancer; 2017 May; 76():197-204. PubMed ID: 28334622
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
Barrett JR; Rendell V; Pokrzywa C; Lopez-Aguiar AG; Cannon J; Poultsides GA; Rocha F; Crown A; Beal E; Michael Pawlik T; Fields R; Panni RZ; Smith P; Idrees K; Cho C; Beems M; Maithel S; Weber S; Erik Abbott D
J Surg Oncol; 2020 Jun; 121(7):1067-1073. PubMed ID: 32153032
[TBL] [Abstract][Full Text] [Related]
16. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
[TBL] [Abstract][Full Text] [Related]
17. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.
Kankava K; Maisonneuve P; Mangogna A; Centonze G; Cattaneo L; Prinzi N; Pusceddu S; Fazio N; Pisa E; Di Domenico S; Bertani E; Mazzaferro V; Albertelli M; Grillo F; Milione M
J Neuroendocrinol; 2021 Aug; 33(8):e13000. PubMed ID: 34268808
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms.
Huang PY; Tsai KL; Liang CM; Tai WC; Rau KM; Wu KL; Huang CC; Chuah SK
Kaohsiung J Med Sci; 2018 Nov; 34(11):650-656. PubMed ID: 30392572
[TBL] [Abstract][Full Text] [Related]
19. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
20. Prognostic predictors for recurrence following curative resection in grade I/II pancreatic neuroendocrine tumours.
Chopde A; Gupta A; Chaudhari V; Parghane R; Basu S; Ostwal V; Ramaswamy A; Puranik A; Shrikhande SV; Bhandare MS
Langenbecks Arch Surg; 2023 May; 408(1):204. PubMed ID: 37212896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
